Published in Medical Letter on the CDC and FDA, December 20th, 2009
that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test. MammaPrint is Agendia's FDA-cleared breast cancer recurrence test, which has been reimbursed by payors since 2008.
Patients across the United States can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed. The coding guidelines for healthcare providers are available at the Centers for Medicare and Medicaid Services (CMS) website at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.